Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CING
Strong SellSinkerCingulate Inc. · Healthcare · United States · $77M · Avg Vol: $722K/d
COMPANY DESCRIPTION
Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to develop improved treatments for ADHD and other neuropsychiatric disorders. The company's competitive advantage lies in its ability to deliver multiple, precisely timed doses of active ingredients from a single tablet, addressing unmet clinical needs. Cingulate operates as a niche biotechnology player focused on optimizing established therapeutic molecules.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 3.6M | 22.3M | — |
| EPS | -1.31 | -2.25 | -1.15 | -3.10 | — | -3.56 | -2.19 | -0.88 | — |
| Shares | 13.5M | 13.5M | 13.5M | 7.3M | -46.2% | — | — | — | — |
| Debt | 5.9M | 3.5M | 5.1M | 8.8M | 14.4% | 6.3M | — | — | — |
| Equity | 3.9M | -6.9M | 7.5M | 2.5M | -13.5% | — | — | — | — |
| Op CF | -15.9M | -15.0M | -18.5M | -17.2M | — | -20.7M | — | — | — |
| Inv CF | -0.2M | -0.2M | -0.2M | -0.2M | — | — | — | — | — |
| Fin CF | 4.9M | 10.0M | 30.8M | 16.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CING are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CING | Cingulate Inc.(you) | $77M | 7 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 6 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%